CSTONE Aktie

 

CS2009 Achieved Key Clinical Validations for Efficacy and Safety As of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded......

CSTONE PHARMA-B (02616.HK) announced its interim results for the six months ended June 2026. Revenue was RMB205 million, up 315% YoY. Loss narrowed to RMB252 million from RMB270 million in the corresponding period of last year. LPS was RMB0.17. (da)~AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically t......

CSTONE PHARMA-B (02616.HK) announced that the Investigational New Drug (IND) application for CS5007, a core candidate drug under its Pipeline 2.0 strategy, has received fast-track approval through the National Medical Products Administration's innovative drug clinical trial review and approval channel in just 23 working days. Th......

Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand. This partnership marks sugemalimab's fifth......

CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights...

CSTONE PHARMA-B (02616.HK) announced that the global multi-center Phase I clinical trial of its EGFR/HER3 bispecific antibody-drug conjugate (ADC) CS5007 has officially received approval from the Human Research Ethics Committee (HREC) in Australia, marking the full initiation of the product's global clinical development.CS5007 i......

SUZHOU, China, June 11, 2026 /PRNewswire/ -- The clinical datasets presented at ASCO 2026 by CStone further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O) backbone therapy. I. Trispecific Design......

CSTONE PHARMA-B (02616.HK) announced multiple key clinical milestones for its core asset CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody). Two posters were officially presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, covering Phase I/II clinical data of CS2009 in first-line and later-line non-small cell......

First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved an objective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with......

CSTONE PHARMA-B (02616.HK) announced that, pursuant to the general mandate to repurchase shares approved by shareholders at the annual general meeting held on June 25, 2025, and any general mandate for share repurchase to be approved by shareholders at general meetings of the Company from time to time in the future, it intends t......

CSTONE PHARMA-B (02616.HK) announced that the first batch of locally manufactured pralsetinib capsules (100 mg), a highly selective RET inhibitor, has completed production and release, and nationwide commercial shipment has officially commenced. This marks a critical step toward autonomous domestic supply chain capabilities for ......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

CStone Pharmaceuticals (02616.HK) announced that at the American Association for Cancer Research (AACR) Annual Meeting held from April 17 to 22, it presented the latest preclinical research results of three internally developed pipeline candidates, including CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC) and CS5008 (DLL3/SSTR2 ADC).......

SUZHOU, China, April 19, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced that the......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

CStone Pharmaceuticals - B (02616.HK) announced its 2025 annual results, reporting revenue of RMB270 million, representing a year-on-year decrease of 33.8%. The loss expanded from RMB91.21 million in the previous year to RMB437 million, with a loss per share of RMB0.31. No final dividend was declared. (de/d)~AASTOCKS Financial N......

Rapid Advancement Across Core R&D Pipeline The global, multicenter Phase I/II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) is actively enrolling patients in Australia and China, and the Phase II IND application has been approved in the US. CS2009 demonstrates an......

Key Highlights: Excellent Safety Profile: As of mid-March 2026, 113 heavily pretreated patients with solid tumors have been enrolled in the Phase I trial of CS2009, with a median follow-up of approximately 6 months. The more mature data continue to show a favorable safety profile, with......

Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for stage III non-small cell lung cancer (NSCLC). This marks the second indication approved for the product in the......

CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial in patients with advanced solid tumors. This marks a significant milestone in the global development......